Eisai Reorganizes R&D Work Into 13 Competitive Units
This article was originally published in PharmAsia News
Executive Summary
Eisai plans to reorganize its research and development operations to make the unit more competitive with the work of other drug makers. Under the plan, MGI Pharma researchers, acquired by Eisai when it bought the firm last year, are to become part of an oncology group, one of 13 units within the R&D division. Each group is to consist of about 100-200 staff ready to operate under the new arrangement in July. The plan includes incentives to the units to compete against each other and other drug makers and each unit is to carry through development from beginning to end. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.